September 22, 2014 5:55 AM ET

Biotechnology

Company Overview of QIAGEN GmbH

Company Overview

QIAGEN GmbH provides sample and assay technologies for research in molecular diagnostics, applied testing, pharma, and academic research. Its products include assay technologies for pathogen detection and genetic analysis, HLA, and haplotyping; molecular diagnostic tests; gene expression and silencing solutions; genotyping solutions for genotyping analysis; sequencing and epigenetics solutions; and plant research, protein science, and whole genome amplification solutions. The company also offers QIAGEN kits for polymerase chain reaction cycling; and biomedical tissue management systems that help in sample processing and analysis. The sample technologies are used to isolate and process DNA, R...

QIAGEN Strasse 1

Hilden,  40724

Germany

Founded in 1984

Phone:

49 2103 29 12000

Fax:

49 2103 29 22000

Key Executives for QIAGEN GmbH

Co-Founder
Age: 62
Senior Vice President of Global Sales and Managing Director
Age: 57
Senior Vice President of Global Research & Development and Managing Director
Age: 54
Vice President of Consumer Marketing Communications
Vice President of Global Human Resources
Compensation as of Fiscal Year 2014.

QIAGEN GmbH Key Developments

QIAGEN GmbH Presents at Berenberg Diagnostics Conference, May-15-2014

QIAGEN GmbH Presents at Berenberg Diagnostics Conference, May-15-2014 . Venue: London, United Kingdom. Speakers: Peer M. Schatz, Chief Executive Officer and Managing Director.

QIAGEN GmbH Presents at Berenberg and Goldman Sachs Second Annual German Corporate Conference, Sep-24-2013 03:45 PM

QIAGEN GmbH Presents at Berenberg and Goldman Sachs Second Annual German Corporate Conference, Sep-24-2013 03:45 PM. Venue: Dolce Munich Unterschleissheim, Andreas-Danzer-Weg 1, 85716 Unterschleissheim, Munich, Germany. Speakers: Roland Sackers, Chief Financial Officer.

QIAGEN and Eli Lilly and Co. Partner to Develop and Commercialize Companion Diagnostics

QIAGEN and Eli Lilly and Co. have signed a master collaboration agreement to develop and commercialize companion diagnostics for combining with Lilly investigational and approved medicines across all therapeutic areas. The contract has been signed due to QIAGEN and Lilly's past work together. The companion diagnostics opens up a patient's molecular information to direct treatment decisions of particular cancers or other diseases. The agreement's financial terms are not disclosed yet. The agreement offers a structure to Lilly and QIAGEN to partner on future projects, focusing on bringing Lilly medicines paired with QIAGEN diagnostics in market. Also, it highlights QIAGEN's position in collaboration with global pharmaceutical companies to provide advantageous of personalized medicine. Earlier, QIAGEN and Lilly have partnered on companion diagnostics that were created to run on QIAGEN's Rotor-Gene Q system.

Similar Private Companies By Industry

Company Name Region
aminoNova AG Europe
X-Zyme GmbH Europe
Algiax Pharmaceuticals GmbH Europe
TOPLAB GmbH Europe
BIOLOG Life Science Institute Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN GmbH, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.